|
Name |
Palmarumycin C15
|
| Molecular Formula | C20H16O7 | |
| IUPAC Name* |
(1'R,2'R,3'S,5'S,7'R,11'R)-spiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene-3,6'-4,12-dioxatetracyclo[5.4.1.01,7.03,5]dodec-9-ene]-2',8',11'-triol
|
|
| SMILES |
C1=CC2=C3C(=C1)OC4([C@@H]5[C@@H](O5)[C@H]([C@]67[C@]4(O6)C(C=C[C@H]7O)O)O)OC3=CC=C2
|
|
| InChI |
InChI=1S/C20H16O7/c21-12-7-8-13(22)19-18(12,27-19)16(23)15-17(24-15)20(19)25-10-5-1-3-9-4-2-6-11(26-20)14(9)10/h1-8,12-13,15-17,21-23H/t12-,13?,15+,16-,17+,18-,19-/m1/s1
|
|
| InChIKey |
XYDXCACUXWHZSX-LYYLEWAKSA-N
|
|
| Synonyms |
Palmarumycin C15
|
|
| CAS | NA | |
| PubChem CID | 11726507 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 368.3 | ALogp: | 0.1 |
| HBD: | 3 | HBA: | 7 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 104.0 | Aromatic Rings: | 7 |
| Heavy Atoms: | 27 | QED Weighted: | 0.463 |
| Caco-2 Permeability: | -5.707 | MDCK Permeability: | 0.00003440 |
| Pgp-inhibitor: | 0.007 | Pgp-substrate: | 0.695 |
| Human Intestinal Absorption (HIA): | 0.456 | 20% Bioavailability (F20%): | 0.251 |
| 30% Bioavailability (F30%): | 0.849 |
| Blood-Brain-Barrier Penetration (BBB): | 0.911 | Plasma Protein Binding (PPB): | 91.69% |
| Volume Distribution (VD): | 0.589 | Fu: | 3.42% |
| CYP1A2-inhibitor: | 0.054 | CYP1A2-substrate: | 0.122 |
| CYP2C19-inhibitor: | 0.04 | CYP2C19-substrate: | 0.377 |
| CYP2C9-inhibitor: | 0.06 | CYP2C9-substrate: | 0.069 |
| CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.395 |
| CYP3A4-inhibitor: | 0.142 | CYP3A4-substrate: | 0.196 |
| Clearance (CL): | 9.719 | Half-life (T1/2): | 0.681 |
| hERG Blockers: | 0.026 | Human Hepatotoxicity (H-HT): | 0.995 |
| Drug-inuced Liver Injury (DILI): | 0.979 | AMES Toxicity: | 0.675 |
| Rat Oral Acute Toxicity: | 0.778 | Maximum Recommended Daily Dose: | 0.78 |
| Skin Sensitization: | 0.113 | Carcinogencity: | 0.141 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.03 |
| Respiratory Toxicity: | 0.959 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003196 | ![]() |
0.784 | D0Q3VE | ![]() |
0.227 | ||
| ENC001988 | ![]() |
0.733 | D08CCE | ![]() |
0.221 | ||
| ENC001999 | ![]() |
0.714 | D01TNW | ![]() |
0.219 | ||
| ENC003239 | ![]() |
0.663 | D08DFX | ![]() |
0.213 | ||
| ENC002330 | ![]() |
0.663 | D06ALD | ![]() |
0.212 | ||
| ENC003238 | ![]() |
0.610 | D06TJJ | ![]() |
0.210 | ||
| ENC003194 | ![]() |
0.602 | D06BQU | ![]() |
0.209 | ||
| ENC003197 | ![]() |
0.570 | D00JRA | ![]() |
0.204 | ||
| ENC003195 | ![]() |
0.524 | D0O6IZ | ![]() |
0.200 | ||
| ENC003442 | ![]() |
0.500 | D0AZ8C | ![]() |
0.197 | ||